IPH 2201, a novel monoclonal antibody targeting NK cells, enters into regulatory pre-clinical development
Approval from the French authorities to start an exploratory Phase II clinical trial in CML with IPH 1101
IPH 2101 (NN 1975), developed in collaboration with Novo Nordisk A/S, was administered for the first time in patients suffering from multiple myeloma
Approval for phase II trial with IPH 1101 in HCV
In-licensing agreement with Cancer Research Technology on novel TLR agent
A set of pharmacological data of IPH 1101 was presented at the ASCO annual meeting
Two additional clinical trials for IPH 1101, including the first Innate's trial outside oncology
New animal model dedicated to studying NK cell activity
IPH 2101 (NN 1975), developed in collaboration with Novo Nordisk A/S, was administered for the first time in humans
Key millestone achieved by Innate Pharma's partner, Clinical Data, Inc.
